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Abstract
Common variants of about 20 genes contributing to AD risk have so far been identiﬁed through genome-wide association
studies (GWAS). However, there is still a large proportion of heritability that might be explained by rare but functionally
important variants. One of the so far identiﬁed genes with rare AD causing variants is ADAM10. Using whole-genome
sequencing we now identiﬁed a single rare nonsynonymous variant (SNV) rs142946965 [p.R215I] in ADAM17 co-
segregating with an autosomal-dominant pattern of late-onset AD in one family. Subsequent genotyping and analysis of
available whole-exome sequencing data of additional case/control samples from Germany, UK, and USA identiﬁed ﬁve
variant carriers among AD patients only. The mutation inhibits pro-protein cleavage and the formation of the active enzyme,
thus leading to loss-of-function of ADAM17 alpha-secretase. Further, we identiﬁed a strong negative correlation between
ADAM17 and APP gene expression in human brain and present in vitro evidence that ADAM17 negatively controls the
expression of APP. As a consequence, p.R215I mutation of ADAM17 leads to elevated Aß formation in vitro. Together our
data supports a causative association of the identiﬁed ADAM17 variant in the pathogenesis of AD.
Introduction
The central theory on Alzheimer disease (AD) pathogenesis
is the amyloid cascade hypothesis with amyloid ß peptides
(Aß), formed from the ß-amyloid precursor protein (APP) as
etiologic agent [1]. The importance of APP metabolism was
conﬁrmed by genome-wide association studies (GWAS)
and reports of rare gene variants in patients with familial
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AD [2]. Historically, the majority of mechanistic studies
was focused on APP processing by alpha-, beta-, and
gamma-secretase to illuminate the cellular pathways of Aß
production as pharmaceutical targets [1]. In addition to APP
metabolism, the so far known AD risk genes are involved in
regulation of the immune system, cholesterol metabolism,
cytoskeleton development, and other. However, there is still
a large proportion of missing heritability that might be
explained by rare but functionally important variants.
We now report a rare single-nucleotide variation (SNV)
of the APP alpha-secretase ADAM17 in a family with
autosomal-dominant late-onset AD that results in loss of
enzyme function. We further identiﬁed a strong negative
regulatory effect of ADAM17 on APP expression in human
brain. This novel function in the newly identiﬁed ADAM17
variant results in an upregulation of APP gene expression
and consequently elevated Aß formation in vitro.
ADAM17, also known as tumor necrosis factor-alpha
converting enzyme (TACE) is a sheddase with over 80 so far
described substrates acting in different physiological pro-
cesses [3]. It was initially described as the enzyme cleaving
membrane bound tumor necrosis factor (TNF)-alpha pre-
cursor to a soluble form [4]. Later on, ADAM17 was
identiﬁed as the ﬁrst alpha-secretase candidate processing
APP [5], followed by ADAM9 and ADAM10 [6, 7]. Rare
variants of ADAM10 have previously been identiﬁed in late-
onset AD patients [8].
Recently, ADAM17 was also identiﬁed as main sheddase
of TREM2. Rare genetic variants of TREM2 considerably
contribute to AD risk [2].
Methods
Clinical characterization of the AD family
All participants gave written informed consent for the
clinical evaluation and genetic analysis of leukocyte DNA.
Clinical phenotyping, whole-genome sequencing (WGS)
and genetic analysis was approved by the ethical review
committee of the Bavarian medical association and by the
Ethics Review Panel of the University of Luxembourg. The
pedigree chart is given in Fig. 1.
The four affected patients with AD (patients 200, 102, 121,
and 124) had a reported age of onset of 60 (patient 200), 69
(patient 102), their APOE status was ε3/4, ε3/4, ε3/3, and ε3/
3, respectively. For patients 121 and 124, age of disease onset
was not reported, age of examination at clinic was 87 and 70,
respectively. Among patients unaffected by AD, the patients
122 and 202 had symptoms of depression; and patient 123
was diagnosed with Parkinson’s disease. Patient 200 was
diagnosed with AD one year after onset of symptoms with a
MMSE score of 28/30. Psychometric testing (CERAD-NAB)
revealed impairment in verbal learning and recognition as
well as in delayed verbal and non-verbal recall. Cranial MRI
was without abnormalities, in particular no atrophy, FDG-
PET showed markedly reduced tracer uptake temporal/ par-
ietal, and occipital (sparing of the primary visual cortex) and
posterior cingulate Gyrus (right > left). One year after ﬁrst
examination clinical and imaging data showed a considerable
progression, MMSE dropped to 26/30 and CERAD-NAB
showed impairment in verbal ﬂuency, verbal learning and
recognition, verbal and non-verbal delayed recall, and
visuoconstruction; cranial MRI revealed cortical atrophy
temporal and parietal as well as hippocampal atrophy (right >
left). The patient died 10 years after onset of disease symp-
toms. No concomitant diseases, drug abuse, or medications
were reported. Neurological examination was normal
and revealed no parkinsonian symptoms. Family members
201, 202, 221, and 222 were unaffected, but too young for a
ﬁnal diagnosis at the time of consulting with an age of
examination at clinic of 55, 49, 55, and 52, respectively. The
two non-affected individuals (122 and 123) had an age of
examination at clinic of 81 and 74, respectively. Blood
samples were taken from ten family members. DNA was
extracted from leukocytes using standard procedures. Affec-
ted family members were pre-screened and negative for
mutations in APP, PSEN1, and PSEN2.
Fig. 1 Pedigree of AD family. The affected and unaffected individuals
are ﬁlled in gray and white, respectively. The APOE status is given
beneath individual identiﬁers. Carriers of the heterozygous variant
(rs142946965) are indicated as C/A and carriers of the wild-type
ADAM17 version are indicated as C/C
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Genome sequencing and analysis
Whole-genome sequencing (WGS) was performed by Com-
plete Genomics Inc. (CG, Mountain View, CA, USA) using
paired-end, nanoarray-based sequencing-by-ligation technol-
ogy [45]. Six individuals of the family were selected for WGS
(Fig. 1 and Suppl. Figure 2B), two affected (102 and 200) and
four unaffected (122, 123, 201, and 202) family members.
After quality control, DNA samples were sent to CG for
sequencing. The sequencing data was processed using the
Standard Sequencing Service pipeline version 2.0. Sequen-
cing reads were mapped against NCBI Build 37.
WGS variant prioritization pipeline
Only single-nucleotide polymorphisms (SNPs) and small
indels (insertions, deletions and block substitutions up to a
size of about 50 nt) were used for further analyses. As input
for our WGS family analysis pipeline [9] we ﬁrst combined
all variants from the genomes of the sequenced family
members into the union of variants using the CG AnalysisTM
Tools (CGATOOLS v.1.5) listvariant command and the CG
‘var’ ﬁles as input. We used CGATOOLS testvariant com-
mand to test each genome for the presence of each allele at
every variant position from the union set of variants. The
average fully called genome fraction, deﬁned as the fraction
of reference bases, for which alleles could be called, was
96.4%, of which 99.1% were covered at least ×5 and 74.9%
with at least ×30. On average, 99.6% of exons as deﬁned by
NCBI RefSeq 37.2 were fully called with at least ×5 and
86% with at least ×30. A statistical summary for all samples
is given in Suppl. Table 3. We detected on average
3,441,899 SNVs and 606,446 indels and substitutions per
genome. The fraction of novel variants, here deﬁned as
variants not previously found in dbSNP build 135, was on
average 0.03 for SNPs and 0.27 for indels and substitutions.
Relationship estimation [10] conﬁrmed all relationships
given the original pedigree information. We removed var-
iants that were not called as high-quality calls (VQHIGH) in
at least one individual. We used ISCA version 0.1.9 [11]
to search for shared haplotype blocks between the two cases
in the families. The shared regions are shown in Suppl.
Figure 1. Variants were then ﬁltered for the shared haplotype
regions. By applying a dominant inheritance model, we ﬁl-
tered for variants that were called heterozygous (or have no-
calls) in cases and were not called in any control genome.
The remaining variants were annotated using ANNOVAR
[12] (version 2015Mar12) using the NCBI RefSeq release
60 and the Ensembl release 74 genome annotations and
multiple annotation databases available from the ANNO-
VAR webpage. We further ﬁltered for exonic regions and
excluded synonymous variants. Candidate variants should
be rare in the general population (here deﬁned by an allele
frequency equal or <1%). Allele frequencies were deter-
mined from the European American population of the 1000
genomes project, the European NHLBI ESP exomes, and
the Non-Finnish European population from the ExAC
project as well as in the control data set CG69 provided by
CG. Since certain genes, like mucins and olfactory recep-
tors, are known to have higher mutation rates, variants in
such genes were excluded. The list of commonly mutated
genes (CMDGenes) is given in Suppl. Table 4. To narrow
down the list of candidate variants, we ﬁltered for genes that
are known to be expressed in brain tissues. The brain-
expressed genes were deﬁned using the data set curated
by [13], and genes expressed in brain regions from the
Human BodyMap 2.0 project processed with the GeneAtlas
tool (http://caballero.github.io/GeneAtlas/). We further
ﬁltered for pathogenicity by considering either loss-of-
function variants (indels, stop gain, and splice-site variants)
or nonsynonymous mutations predicted to be deleterious by
at least 5 out of 7 pathogenicity scores (SIFT, Poly-
phen2_HDIV, Polyphen2_HVAR, LRT, Mutationtaster,
PROVEAN, MetaSVM, fathmm-MK_coding_pred, as
given by dbNSFP3.0a [14]) and two out of four conserva-
tion scores (DAMN, CADD, GERP, SiPHY). A list of
candidate genes related to AD and neurodegenerative dis-
eases were collected from various GWAS studies in
dbGAP, the Alzgene database [15] and the Genotator tool
[16]. In total, we collected a ﬁnal list of 2352 candidate
genes related to neurodegenerative diseases (Suppl. Table 5,
NDGenes). The variants were examined using the candidate
gene list and the KGGseq tool [17]. Each variant was tested
if the affected gene co-occurred with any candidate gene
within a certain pathway or if it was connected within a ﬁrst
neighborhood to one of the neurodegenerative candidate
genes within a protein–protein interaction network using the
STRING database [18]. The whole ﬁltering strategy is
shown in Suppl. Figure 2A.
Genetic and linkage analysis
For linkage analysis, high-quality SNP positions (complete
call rate over all individuals (VQHIGH status in CG var ﬁles)
were extracted from the WGS data. Using variants in linkage
disequilibrium (LD) for the linkage analysis might lead to
false positive results. Hence, the variants with high LD were
removed by using PLINK 1.9 [19]. Further thinning of var-
iants was performed by using mapthin software [20]. A set of
2000 variants per chromosome along with the identiﬁed
variants segregating with the disease through the pedigree
were used to check for genotype errors and Mendelian
inconsistencies using MERLIN [21] and were subsequently
removed if they were identiﬁed as errors. Remaining variants
were used for linkage analysis and their genomic positions
were linear interpolated based on hapmap genetic map (2011-
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01_phaseII_B37). MERLIN was used to perform both hap-
lotyping and multipoint parametric linkage analysis with a
rare dominant disease model with a disease frequency of
0.0001 and penetrance of 0.0001,1.0,1.0. Haplotyping results
were visualized using Haplopainter [22] (Suppl. Figure 2B-
C). Using the R package ‘paramlink’ [23] we calculated the
power of the pedigree given as the maximal LOD score
(1.20412) under an autosomal-dominant inheritance model
and 10,000 simulated markers. Relationship detection
between all individuals was performed using the software
GRAB [10]. Validation of results by Sanger sequencing was
carried out by Seq IT GmbH, Kaiserslautern, Germany.
Expression correlation analysis of ADAM17 and APP
in human brain tissue
Correlation analysis of APP and ADAM17 gene expression
was carried out using a sample set obtained from fresh
frozen post-mortem prefrontal cortex of 201 AD samples
and 83 cognitively healthy controls, provided by The
Netherland Brain Bank (NBB). A second sample set used
for independent validation of results contained 57 fresh
frozen post-mortem human temporal cortex samples (33 AD
samples and 24 cognitively healthy controls) provided by
Brain Bank Munich (MUC). Full sample characteristics are
given in Suppl. Table 2. Total RNA was extracted from
human brain tissue using either miRNeasy Mini Kit or
RNeasy Lipid Tissue Mini Kit (Qiagen) according to
manufacturer’s protocol including on-column DNA diges-
tion with RNase free DNase Set (Qiagen). Total RNA was
ampliﬁed and labeled with biotin using Ambion® Illumina®
TotalPrep™ RNA Ampliﬁcation Kit (Ambion) according to
manufacturer’s protocol. cRNA was eluted in 50 μl
nuclease-free water and precipitated using ammonium
acetate (NH4OAc) when concentration was <150 ng/μl.
Direct hybridization of 750 ng biotin labeled cRNA to
Illumina® Sentrix BeadChips HumanHT-12 v4 (Illumina)
was conducted according to manufacturer’s protocol.
Whole-genome gene expression analysis incorporated
47,231 markers per sample including coding as well as non-
coding transcripts based on Human RefSeq 38 (NCBI
RefSeq database) and supplementary UniGene content.
Processed BeadChips were scanned using the HiScan
(Illumina). In the ﬁrst quality check step, background sub-
traction, and quantile normalization were executed with
GenomeBead Studio Module for gene expression. Markers
with a detection p-value ≥ 0.05 were considered as no-call.
Call rates for each marker were calculated separately in both
groups (AD vs. control). Markers with a call rate <90 % in
both groups were considered as non-informative and were
excluded from further statistical analysis. Signal intensities
were log2 transformed for further analysis. Correlation
between the expression of ADAM17 and APP was tested
using the linear model ﬁt function (lm) in the R package. p-
value of the coefﬁcient (slope of the ﬁt) and adjusted R2
were reported. Correlation between ADAM17 and ADAM17
target gene expression was tested using the correlation test
in R.
Additionally, the MERAV database and analysis tool
[30] was used to examine gene expression correlations
between ADAM17 and APP in non-brain and brain tissues
from public databases like ArrayExpress, GEO and the
human body index. MERAV is a tool for comparing gene
expression across different human tissues and cell types.
The quantile normalized log-transformed expression
values for the four genes for normal non-brain (502) and
normal brain tissues (186) were downloaded and Pearson
correlation between gene expression for all gene pairs
were calculated using tool cor.test in R. Additionally,
we tested the signiﬁcance of the difference between cor-
relations coefﬁcients obtained for the non-brain and brain
tissues using the R library psych and the one-sided paired
r test.
Generation of ADAM17 variants
ADAM17 cDNA was derived from clone HsCD00342307
(Harvard Medical School). Wild-type ADAM17 was ampli-
ﬁed and digested with KpnI and BamHI primers (for primer
sequences see Suppl. Table 7), and ligated into pCDNA3.1
(+) (Invitrogen # V790-20). Site-directed mutagenesis of
ADAM17 was done via PCR-driven overlap extension (PMID
17446874). For p.R215I and p.E406A mutagenesis primer
sequences are given in Suppl. Table 6. Hybridization of 5′
and 3′ portions of ADAM 17 variants was used for the
ampliﬁcation of full length ADAM17 variants. For subcloning
into pcDNA3.1(+) the full length ADAM17 variants were
enriched via PCR ampliﬁcation using the primers KpnI_f and
BamHI_r. Digestion and ligation steps were done as described
above for wild-type ADAM17. Bacterial cultures with
ADAM17 constructs were grown at 24 °C for 48 h.
Cell culture
SH-SY5Y cells stably expressing human APP695 carrying
the Swedish double mutation (in pcDNA3.1, selection with
0.3 mg/ml hygromycin) were kindly provided by Tobias
Hartmann and Marcus Grimm (Saarland University). SH-
SY5Y cells were stably transfected with expression con-
structs for ADAM17 variants (in pcDNA3.1, selection with
500 μg/ml geneticin). Cells were grown in DMEM with
selection antibiotics and 10% fetal calf serum (FCS). For
rescue experiments, cells were supplied with media con-
taining 100 nM TAPI-0 (SantaCruz) or equal volume of
DMSO as control. Medium was changed every second day,
cells were checked for mycoplasma contamination.
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Protein and gene expression analyses in cells
The amounts of ADAM17 and APP in cellular lysates were
determined by standard Western blotting techniques. Anti-
bodies directed against ADAM17 or APP were obtained
from commercial suppliers (ADAM17/TACE C15 and H-
300, SantaCruz; APP 6E10, Covance). For lysis, cells were
washed with ice-cold PBS and resuspended in ice-cold
standard RIPA buffer containing 10 mM 1,10 phenantroline
(Sigma-Aldrich) and protease inhibitor cocktail (Complete,
Roche). Blots were developed using the SuperSignal West
Femto Chemiluminescent Substrate (Pierce) and analyzed
using the Peqlab FUSION XPress Imaging System. Beta-
Actin or Alpha-Tubulin was analyzed as loading control.
For statistical analysis, signals were normalized to loading
controls and statistical signiﬁcance was determined by non-
parametric Kruskal–Wallis test and Dunn's multiple com-
parison test using Prism software (version 6.0d; Graphpad).
Multiplicity adjusted p-values are given. Only relative sig-
nals (to control) were combined from different blots and all
samples represent biological replicates.
Secreted Aβ40 and Aβ42 was quantiﬁed in cell culture
media using commercial ELISA kits (EZBRAIN Aß40 and
Aß42 Brain ELISA Kit, respectively Millipore). For ELISA,
culture media was removed, cells were washed with PBS,
then incubated in fresh medium containing 1% FCS for
48 h. After incubation, medium was collected, spun down
and supernatant was used for measurements. Statistical
signiﬁcance of data was determined by ANOVA with
Fisher's LSD test for pairwise comparisons using Prism
software (version 6.0d; Graphpad).
Total RNA from cells was prepared using miRNeasy
Mini Kit (Qiagen) according to manufacturer’s protocol.
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems) was used for cDNA synthesis. Levels of APP
mRNA expressed in SH-SY5Y cells were determined by
quantitative RT-PCR using the Applied Biosystems 7500
Fast Real-Time PCR System. Samples were measured in
triplicates, and calculations were performed using the Prism
software (Graphpad, version 6.0d). Values for APP were
normalized to 18 S expression determined in parallel in the
respective samples. Fold changes were calculated by
applying the 2^-ddCT method.
Results
Identiﬁcation of an ADAM17 variant associated with
familial AD
We identiﬁed an SNV of ADAM17 co-segregating with the
disease in a family with an autosomal-dominant pattern of
inheritance of late-onset AD. Affected family members
lacked pathogenic mutations of known AD genes. Whole-
genomes of six family members (two affected and four
unaffected, Fig. 1) were sequenced and analyzed by prior-
itizing rare, potential damaging variants that segregated
with the disease. We searched for segregating variants by
applying an autosomal-dominant inheritance model. In total
7,009,082 variants (SNPs and indels) different from the
reference genome were identiﬁed in at least one family
member. After strict quality ﬁltering, 6.2 million variants
remained. Due to the pedigree structure, we ﬁltered for
shared haplotype regions (Suppl. Figures 1 and 2A)
between the two affected individuals (n= 3,903,193) and
autosomal-dominant mode of inheritance (n= 187,733)
ﬁltering for heterozygous variants in the two affected and
homozygous wild-type genotypes in the unaffected indivi-
duals 122 and 123. To further narrow down the list of
variants, we screened for rare variants (n= 18,597) with
predicted exonic defects (n= 64). After ﬁltering out com-
monly mutated (n= 51) and variants in genes that are not
brain-expressed (n= 25), we prioritized the remaining
variants according to their predicted pathogenicity and
conservation (n= 11, Suppl. Figure 2A, Suppl. Table 1).
Only two out of the nine candidate variants were known
relevant candidate genes (ADAM17 and ADRA2A). Addi-
tionally, we performed linkage analysis for the pedigree
using MERLIN [21]. Only two variants (ADAM17 and
DDHD2) fall into a region that showed the maximal LOD
score (1.20) for this pedigree as calculated with ‘paramlink’
[23] (Suppl. Figure 2B-C). The ADAM17 variant
(NM_003183:exon6:c.G644T:p.R215I; rs142946965) was
the only variant in an AD relevant gene predicted patho-
genic by 7 out of 8 prediction programs (SIFT, Polyphen
(HDIV/HVAR)), LRT, MutationTaster, Provean and
FATHMM), conserved by three out of four conservation
scores (DAMN, GERP, SiPHy) and additionally located
within the maximal LOD score region of the pedigree. The
presence of the heterozygous ADAM17 variant
(rs142946965) in the two affected family members was
conﬁrmed by Sanger sequencing and identiﬁed in two
additional affected family members (121, 124, Fig. 1) that
have not been analyzed by whole-genome sequencing
(WGS). Also, the absence of the variant was veriﬁed in the
four non-affected family members and in the non-affected
family members 221 and 222 (Fig. 1) that have not been
analyzed by WGS. The information generated by Sanger
sequencing of additional family members results in a
maximal LOD score of 1.81 as calculated with ‘paramlink’.
Together, our genetic approach including WGS, con-
ﬁrmation, and extension by Sanger sequencing identiﬁed
the SNV rs142946965 of ADAM17 to co-segregate with AD
cases among the analyzed family members.
To further explore the possible relevance of the
rs142946965 variant in AD we genotyped a German cohort
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(N= 1045: 969 cases, 76 controls) and analyzed this variant
in exome sequencing data from a UK cohort (N= 571: 331
cases, 240 controls), and a cohort from the USA
(Washington Heights-Hamilton Heights-Inwood Commu-
nity Aging Project; WHICAP; N= 3834: 1567 cases, 2267
controls). The variant was not present within the control
subjects. The same was true for an additional cohort of 468
unrelated Caucasian individuals of age 60 or higher from
several UK and US brain banks who did not have a neu-
rodegenerative disease diagnosis or disease-associated
neuropathology at the time of death (Healthy exomes
database, version 1.0) [24]. We identiﬁed ﬁve additional
heterozygous variant carriers among AD subjects, one in
each of the German and UK cohort, and three in the US
cohort. The German variant carrier had an age of disease
onset of 79 and the APOE status was ε2/3. The British
variant carrier had an age at death of 92, with a hypothe-
sized onset of disease at the age of 84 years, the APOE
status was ε3/4. The three variant carriers in the US cohort
had an age of disease onset of 85, 85, and 90, and one
patient carries the APOE ε4 allele. All three US variant
carriers were of Hispanic ethnicity.
Subsequent screening of genetic databases revealed an
ultra-rare occurrence of the heterozygous rs142946965
variant in the European population (ESP6500_ea: 0.000077,
1000g_eur: 0.000199681, ExAC_NFE: 0.0001049) and no
presence in any non-European populations. In the gnomAD
database (http://gnomad.broadinstitute.org) from February
2017 the variant was present in 9 out of 138,390 individuals
(allele frequency of 0.0000325), only in the heterozygous
form and only present in the non-Finnish European
population.
The p.R215I mutation affects pro-protein convertase
cleavage of ADAM17
A disintegrin and metalloprotease family (ADAM) members
are multidomain proteins synthesized as latent precursors
that are converted to mature, active enzymes by pro-protein
convertase [25]. Enzymatic activity is inhibited via a
cysteine switch mechanism forming a complex between a
cysteine residue within the pro-domain and the zinc ion in
the active center of the catalytic domain [26]. Activation of
ADAMs requires proteolytic cleavage of the pro-domain.
Pro-ADAM17 is activated in the trans-Golgi-network
through furin cleavage at the last four amino acids preced-
ing the catalytic domain [27]. The identiﬁed rs142946965,
R215I variant of ADAM17 causes a missense mutation
changing positively charged, polar arginine to the non-polar,
hydrophobic amino acid, isoleucine. The change is located at
position 215 (corresponding to the canonical sequence of
human ADAM17), right next to the pro-protein convertase
cleavage motif (spanning positions 210–214 [28]),
suggesting a possible interference with pro-protein con-
vertase binding to ADAM17. To analyze possible effects of
the mutation on ADAM17 biochemical function, we gen-
erated neuroblastoma (SH-SY5Y) cell lines stably over-
expressing the newly identiﬁed variant of ADAM17
(p.R215I). In addition, we generated SH-SY5Y cells over-
expressing human, wild-type ADAM17 (wild-type), and a
catalytically inactive/dominant-negative form of ADAM17
(p.E406A), known from literature [29].
Over-expression of ADAM17 in cells resulted in sig-
niﬁcant upregulation of total and pro-ADAM17 protein
levels as compared to the parental cell line (control). This
was true for all three variants, p.R215I, p.E406A, and wild-
type ADAM17 (Fig. 2a–c). There was no signiﬁcant dif-
ference between the p.R215I variant, the p.E406A variant
and the wild-type variant of pro-ADAM17 levels. In con-
trast, levels of the shorter, mature form of ADAM17 lacking
Fig. 2 The R215I variant affects maturation of ADAM17. a Western
blot showing ADAM17 (A17) protein expression in SH-SY5Y cells,
over-expressing wild-type (wt) ADAM17, a dominant-negative form
(E406A), or the newly identiﬁed AD variant of ADAM17 (R215I).
The parental cell line was analyzed as control, actin-beta was analyzed
as loading control (Actin). b, c Quantiﬁcation of pro-ADAM17 signals
shows signiﬁcant upregulation in cell lines over-expressing ADAM17
variants (n= 8; p(wt)= 0.0057; p(E406A)= 0.0009; p(R215I)=
0.0014), respectively, as compared to the parental cell line (control).
Quantiﬁcation of mature ADAM17 signals only shows signiﬁcant
upregulation in cell lines over-expressing wild-type ADAM17 (n= 8;
p(wt)= 0.0092), as compared to the parental cell line (control).
Asterisks indicate signiﬁcance. Error bars indicate mean with SD
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the pro-domain, were signiﬁcantly upregulated exclusively
in cells over-expressing wild-type ADAM17, but not altered
in cells over-expressing p.R215I or p.E406A variants, as
compared to control cells, respectively (Fig. 2a, c). These
results demonstrate that as previously described elsewhere
for the inactive p.E406A variant, pro-protein convertase
cleavage is severely impaired in the newly identiﬁed
ADAM17 variant (p.R215I), resulting in a lack of mature,
catalytically active ADAM17 molecules.
ADAM17 inhibits APP expression in vitro
Three members of the ADAM family, ADAM9, ADAM10,
and ADAM17, show APP alpha-secretase activities [5–7].
The alpha-secretase initiates the non-amyloidogenic path-
way by cleaving APP within the beta-amyloid sequence,
which precludes the formation of beta-amyloid and further
generates the neurotrophic and neuroprotective soluble N-
terminal fragment of APP (sAPPα).
To analyze the effect of ADAM17 variants on Aß for-
mation, we created SH-SY5Y cell lines over-expressing both
human APP and ADAM17 (wild-type, p.E406A, or p.R215I
variants, respectively). Maturation of mutated ADAM17 was
again reduced in these cells (data not shown).
We ﬁrst measured total APP protein and gene expression
in ADAM17 and APP transgenic SH-SY5Y cell lines.
Surprisingly, APP protein and gene expression were sig-
niﬁcantly reduced in cells expressing wild-type ADAM17
as compared to control cells expressing mutated forms of
ADAM17, or APP only (Fig. 3a–c). Downregulation
of APP gene expression in cells expressing wild-type
ADAM17 was also observed in cells expressing endogen-
ous APP (Suppl. Figure 3). In accordance with the observed
reduction of APP expression by wild-type ADAM17, Aß40,
and Aß42 secretion as measured by ELISA was upregulated
in cells expressing the R215I variant as compared to cells
expressing wild-type ADAM17 (Fig. 3d, e).
To analyze whether the observed downregulation of APP
expression could be rescued by ADAM17 inhibition, we
treated SH-SY5Y cells expressing both, APP and wild-type
ADAM17, with a metalloprotease inhibitor (TAPI-0).
Treatment of cells with 100 nM TAPI-0 inhibitor for 16 h
had no signiﬁcant effect on APP expression, but long-term
treatment (6 days) with regular medium change resulted in
full rescue of APP gene and protein expression, suggesting
an active functional role of ADAM17 in regulation of APP
expression (Fig. 3a–c).
ADAM17 is negatively correlated with APP
expression in human brain
We next analyzed a possible correlation between APP and
ADAM17 gene expression in human brain. Analysis of gene
expression data from 284 human prefrontal cortex samples
(NBB data: 201 AD patients and 83 controls, Suppl. Table 2)
showed a very strong negative correlation (p= 2.2×10−16, r2=
0.55 for the average of APP markers ILMN_2404065,
ILMN_2404063, and ILMN_1653283 compared to the average
of ADAM17 markers ILMN_1765779 and ILMN_2121068) of
ADAM17 and APP mRNA both, in AD and control brains (Fig.
4a). This negative correlation was replicated in an independent
sample comprising 57 human temporal cortex samples (MUC
data: 33 AD patients and 24 controls, p= 5.8×10−10, r2= 0.44,
Suppl. Table 2; Fig. 4b). These results strongly argue for a
general functional connection of both genes in human brain
which is not restricted to AD patients.
To ﬁnd out whether ADAM17 expression might be cor-
related with expression of its other targets as well, we used
the human brain gene expression data set (NBB) to check
for possible correlations of ADAM17 with 71 known
ADAM17 targets. Among the analyzed ADAM17 target
genes (Supplementary Table 7), ADAM17 only showed
high correlation (deﬁned as Pearson correlation coefﬁcient
of ±0.7 to 1) with PRNP (−0.77) and APP (−0.74). Other
AD related targets, such as TREM2 or SORL1 only had low
to moderate correlation coefﬁcients (Suppl. Table 7).
In addition, we explored possible correlations between
APP and both other alpha-secretase genes, ADAM9 and
ADAM10, using our human brain gene expression data sets.
We observed a very weak negative correlation of ADAM9
with APP gene expression (NBB data: p= 0.06, r2= 0.01;
MUC data: p= 0.02, r2= 0.06; for ADAM9 marker
ILMN_1727524). For ADAM10, a weak positive correlation
with APP expression was observed (NBB data: p= 3.3 ×
10−8, r2= 0.09; MUC data: p= 2.6 × 10−4, r2= 0.17; for
the average of ADAM10 markers ILMN_1718946 and
ILMN_2148360).
We next evaluated possible correlations between APP
and ADAM17 gene expression in brain and non-brain tis-
sues from public databases using the MERAV tool [30].
Again, a signiﬁcant negative correlation was observed in
brain tissues (r=−0.27, p= 0.00024), whereas in non-
brain tissues, no correlation between ADAM17 and APP
was present (r= 0.0089, p= 0.3421).
Together, we found that among known ADAM17 substrates,
gene expression of APP and PRNP showed the highest observed
overall correlation with ADAM17 gene expression in the brain.
Both correlations were negative and APP gene expression was
not signiﬁcantly correlated with gene expression of ADAM9 and
ADAM10.
Discussion
Using WGS we identiﬁed a single rare nonsynonymous
variant p.R215I in ADAM17 shared in all four affected
A rare loss-of-function variant of ADAM17 is associated with late-onset familial Alzheimer disease
individuals and co-segregating in an extended family with
an autosomal-dominant pattern of late-onset AD. We cannot
exclude the possibility that other co-segregating variants are
involved in AD pathogenesis as well. However, the
ADAM17 variant was the only variant in a so far known AD
relevant gene that was also predicted pathogenic by 7 out of
8 prediction programs, conserved by three out of four
conservation scores and additionally located within the
maximal LOD score region of the pedigree. Subsequent
follow-up of this variant in genotyping and whole-exome
sequencing data in 5450 additional case/control samples
from Germany, the UK and the USA identiﬁed ﬁve het-
erozygous variant carriers among AD patients and none
within the control subjects. Information derived from
genetic population databases revealed an ultra-rare allele
frequency among Europeans and absence in non-European
populations.
During the functional characterization of the new
ADAM17 variant, we demonstrated failure of ADAM17
maturation causing a loss of alpha-secretase function. Pre-
viously, two rare missense mutations of alpha-secretase
ADAM10, a close relative of ADAM17, were identiﬁed in
autosomal-dominant families with AD [8]. Interestingly, as
reported here for ADAM17, these ADAM10 mutations
were demonstrated to impair pro-domain cleavage as well
[31]. Loss of ADAM10 function also resulted in enhanced
Aß formation in mice [31].
Focusing on the ADAM17 target APP, we identiﬁed a
surprising strong negative correlation between ADAM17
and APP gene expression in human brain tissue. Inter-
estingly, a recent report addressing the strongest identiﬁed
genetic risk factor for sporadic AD so far, Apolipoprotein
E (APOE), has uncovered a yet unknown differential
effect of APOE2, APOE3, and APOE4 variants on APP
Fig. 3 APP expression is downregulated by ADAM17. a Western blot
showing total APP protein expression in lysates of cells over-
expressing APP and respective variants of ADAM17 (A17).
b Quantiﬁcation of total APP protein signals shows signiﬁcant
downregulation in cells over-expressing wild-type (wt) ADAM17 and
APP as compared to cells only expressing APP (APP control). No
signiﬁcant change was observed in cells expressing ADAM17 E406A
and R215I variants, respectively, as compared to APP control cells.
Rescue of APP expression was observed in A17 wt cells after treat-
ment with ADAM inhibitor TAPI-0. c APP gene expression is
signiﬁcantly downregulated in cells over-expressing A17 wt and APP
as compared to APP control cells (n= 9, p(wt)= 0.001). Rescue of
APP expression was observed in A17 wt cells after treatment with
ADAM inhibitor TAPI-0 (n= 3). APP was also signiﬁcantly down-
regulated in the parental cell line that did not over-express APP (n= 9,
p= 0.0341). d ELISA of Aß40 or e Aß42 in media of SH-SY5Y cells
over-expressing APP shows signiﬁcant downregulation of both Aß
forms in A17 (wt), (p(Aß40) < 0.0001; p(Aß42))= 0.0007; n= 4)
cells as compared to APP control cells. For b to e: Asterisks indicate
signiﬁcance. Error bars indicate mean with SD
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transcription [32]. These results corroborate a central
involvement of APP in AD pathology and shed new light
on the role of differential APP gene expression in AD
pathogenesis.
Using cellular models, we conﬁrmed that over-
expression of wild-type ADAM17 caused a reduction of
APP gene and protein expression, suggesting a novel
mechanism of APP expression regulation by ADAM17. In
literature, different pathways are described potentially
linking ADAM17 to APP transcription. von Rotz et al.
demonstrated that AICD regulates transcription of APP after
being transported to the nucleus; but AICD generated
through the alpha-secretase pathway is rather unstable and
rapidly degraded [33, 34]. Also, cleavage of signaling
receptors such as the p75 neurotrophin receptor or the
TGFß-receptor by ADAM17 could potentially inﬂuence
APP transcription [35–38]. However, the exact mechanism
has yet to be determined.
In contrast to wild-type ADAM17, over-expression of
the R215I version of ADAM17 failed to reduce APP
expression and caused elevated Aß levels in vitro. In line
with our results, it was previously reported that induction of
ADAM17 coincided with downregulation of APP in rat
brain and HEK293 cells, and reduced Aß accumulation and
AD-like pathology in the Tg2576 mouse model [39–41].
Moreover, decreased ADAM17-mediated alpha-secretase
activity was previously shown to promote disease progres-
sion in prion disease and AD and to increase accumulation
of Aß and pathogenic prions [42]. In cancer cells, APP was
demonstrated to regulate ADAM17 gene expression [43].
Together, these ﬁndings suggest that the R215I mutation of
ADAM17 causes loss of alpha-secretase function and con-
sequently elevated Aß production.
Given that over 80 substrates of ADAM17 have been
identiﬁed so far, the newly identiﬁed variant of ADAM17
most probably causes multiple effects that might play a role
in AD pathogenesis. For example, ADAM17 has recently
been demonstrated to be the main sheddase of TREM2, a
transmembrane protein that was identiﬁed as AD risk factor
by GWAS [2, 44]. However, the exact mechanisms how
ADAM17 contributes to AD pathogenesis remain to be
analyzed in the future.
Our results corroborate an involvement of the alpha-
secretase ADAM17 in AD pathogenesis by identifying a
novel rare loss of function variant of this gene. Future large-
scale genetic sequencing approaches aiming at the identi-
ﬁcation and gene-based analyses of ADAM17 variants are
mandatory to fully understand the genetic contribution of
ADAM17 to AD.
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